Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Rain Oncology to $17 from $18 and keeps a Buy rating on the shares. There were no major updates of significance in the company’s Q4 report, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RAIN:
- Rain Oncology price target raised to $19 from $12 at H.C. Wainwright
- Rain Oncology reports Q4 EPS (70c), consensus (56c)
- Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
- TipRanks ‘Perfect 10’ List: There’s an Opportunity Brewing in These 2 Stocks
- Rain Oncology delayed data could be positive sign, says JonesResearch
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue